Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting
Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatmentUpdated data from phase III CLL14 study of Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) showed more than 60% of previously untreated people with chronic lymphocytic leukaemia remained in remission five years after starting treatment[1]Final analysis of phase III GALLIUM study showed meaningful improvement in progression-free survival was main...
Source: Roche Media News - June 10, 2022 Category: Pharmaceuticals Source Type: news

U.S. FDA approves Foundation Medicine ’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)
FoundationOneCDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solidtumours for whom treatment withRozlytrek may be appropriateThis approval marks the first and only companion diagnostic indication forRozlytrek, and another important milestone intumour-agnostic approaches for people living with rare cancersRoche is a leader in drivingpersonalised healthcare around the world through validated diagnostic tools, genomic insights and a continued focus on drug developmentBasel, 9 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that ...
Source: Roche Media News - June 9, 2022 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adu...
Source: Roche Media News - June 9, 2022 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma
Lunsumio® (mosunetuzumab) is the first CD20xCD3 T-cell engaging bispecific antibody available to treat the most common slow-growing form of non-Hodgkin lymphoma, follicular lymphoma (FL)Lunsumio represents a new type of immunotherapy that is a chemotherapy-free, off-the-shelf, fixed-duration treatment option that could improve outcomes for people who have relapsed or are refractory to multiple previous treatmentsApproval is based on the phase I/II GO29781 study, whereLunsumio induced high complete response rates, with the majority of complete responses lasting for at least 18 months in people with heavily pre-treated FLBa...
Source: Roche Media News - June 8, 2022 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
Approval based on interim RAINBOWFISH data which show pre-symptomatic babies treated withEvrysdi for at least one year were able to sit, stand and walkPrescribing information updated with FIREFISH data showing the majority of symptomatic babies treated withEvrysdi for at least two years could sit for at least five secondsEvrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to dateBasel, 31 May 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include babies under...
Source: Roche Media News - May 31, 2022 Category: Pharmaceuticals Source Type: news

New pivotal data demonstrate clinical benefit of Roche ’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma
Data to be presented for the first time at ASCO and EHA 2022 show glofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma ¹ Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphomaGlofitamab is part of Roche ’s industry-leading CD20xCD3 bispecific antibody development programme, which aims to address the diverse needs and preferences of people with blood cancers Basel, 27 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new p...
Source: Roche Media News - May 27, 2022 Category: Pharmaceuticals Source Type: news

New pivotal data demonstrate clinical benefit of Roche ’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma
Data to be presented for the first time at ASCO and EHA 2022 showglofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma1Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphomaGlofitamab is part of Roche ’s industry-leading CD20xCD3 bispecific antibody developmentprogramme, which aims to address the diverse needs and preferences of people with blood cancersBasel, 27 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new pivotal data on i...
Source: Roche Media News - May 27, 2022 Category: Pharmaceuticals Source Type: news

Roche ’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma
First new treatment option in more than 20 years to show a clinically meaningful improvement in progression-free survival is approved for people with previously untreated diffuse large B-cell lymphoma (DLBCL)Approval is based on pivotal data from the phase III POLARIX study, where Polivy plus R-CHP significantly improved progression-free survival with comparable safety versus the standard of care, R-CHOPFirst-line treatment with Polivy plus R-CHP has the potential to reduce the burden on patients and healthcare systems, associated with disease progression ¹Basel, 25 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today anno...
Source: Roche Media News - May 25, 2022 Category: Pharmaceuticals Source Type: news

Roche develops unique PCR tests to detect the monkeypox virus
Roche and its subsidiary TIBMolbiol have developed three differentLightMix® Modular Virus kits for the detection of themonkeypox virusMultiple clusters ofmonkeypox virus have been reported in non-endemic countries, and the World Health Organization (WHO) expects more cases will be identified as surveillance expandsUse of these new research test kits assess the spread of the virus and can help monitor the potential impact of therapeutics, vaccines and public health interventionsBasel, 25 May 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and its subsidiary TIB Molbiol have developed three unique LightMix® Modular Virus kits ...
Source: Roche Media News - May 25, 2022 Category: Pharmaceuticals Source Type: news

Roche develops unique PCR tests to detect the monkeypox virus
Roche and its subsidiary TIB Molbiol  have developed three different  LightMix ® Modular Virus kits for the detection of the monkeypox virus  Multiple clusters of monkeypox virus have been reported in non-endemic countries, and the World Health Organization (WHO) expects more cases will be identified as surveillance expandsUse of these new research test kits assess the spread of the virus and can help monitor the potential impact of therapeutics, vaccines and public health interventionsBasel, 25 May 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and its subsidiary TIB Molbiol have developed three unique L...
Source: Roche Media News - May 25, 2022 Category: Pharmaceuticals Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data on glofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Onc...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news

Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare
Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leadinghaematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncol...
Source: Roche Media News - May 24, 2022 Category: Pharmaceuticals Source Type: news

Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
Almost half of the world ’s population has no or limited access to diagnosticsThis situation is especially acute in low- and middle-income countries (LMICs) where diagnostics plays a critical role for treating and containing the spread of infectious diseases such as Tuberculosis (TB) and HIVNew partnership between Roche and the Global Fund supports low- and middle-income countries in broadening access to diagnostics, helping millions of previously undiagnosed people with TB and HIV get diagnosed and eventually treatedBasel, 12 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY), through its Global Access Program, and The Globa...
Source: Roche Media News - May 12, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer
The SKYSCRAPER-01 study evaluatingtiragolumab plusTecentriq did not meet its co-primary endpoint of progression-free survivalThe other co-primary endpoint of overall survival was immature and the study will continue until the next planned analysisThetiragolumab developmentprogramme continues as planned in non-small cell lung cancer and other cancer typesBasel, 11 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from its phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq ® (atezolizumab) versus Tecentriq alone as an initial (first-line) tre...
Source: Roche Media News - May 11, 2022 Category: Pharmaceuticals Source Type: news